Marinus (MRNS) Price & Analysis

Compare

1,214 Followers

MRNS Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.22 - $10.50

Previous CloseN/A

Volume358.63K

Average Volume (3M)N/A

Market Cap

$30.37M

Enterprise Value$153.73M

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta2.13

Next Earnings

Mar 11, 2025

EPS Estimate

-0.33

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.47

Shares Outstanding53,869,000

10 Day Avg. VolumeN/A

30 Day Avg. VolumeN/A

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)-0.45

Price to Sales (P/S)0.96

P/FCF Ratio0.00

Enterprise Value/Market Cap5.06

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$0.95

Price Target Upside72.73% Upside

Rating ConsensusHold

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Potential PartnershipsThere is potential for a partner or acquirer for ZTALMY given its established launch success in patients with CDKL5-deficiency disorder.

Product ApprovalZtalmy (oral ganaxolone) is approved in several countries as the only treatment for CDKL5 deficiency disorder.

Revenue GrowthZtalmy performance was solid with Q3 2024 net product revenue of $8.5 million, up 56% year-over-year.

Bears Say

Clinical Trial ResultsThe Ph. III trial of ganaxolone in TSC failed to meet the primary endpoint.

Financial PerformanceMarinus reported a Q3 net loss of $24.2MM or $0.42/share.

Revenue GuidanceManagement tweaked down guidance for the full year 2024 to $33-34 million from $33-35 million, reflecting modest patient additions.

Marinus News

Marinus Pharmaceuticals Inc (MRNS) Q4 Earnings Cheat Sheet

Marinus Pharmaceuticals Inc (MRNS) is scheduled to report 4th quarter earnings on 03/11/2025. Regarding Q4 estimates, Wall Street...

5M ago

MRNS

Immedica Pharma Completes Acquisition of Marinus Pharmaceuticals

An update from Marinus ( ($MRNS) ) is now available. On February 11, 2025, Immedica Pharma AB completed...

6M ago

MRNS

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

7M ago

CVM

CDTX

Morning Movers: Boeing lower after Jeju Air 737-800 crash in South Korea

Check out this morning’s top movers from around Wall Street, compiled by The Fly. HIGHER – Marinus Pharmaceuticals...

7M ago

VRA

Marinus Ends Agreements Amid Strategic Review

Marinus ( ($MRNS) ) has issued an announcement. Marinus Pharmaceuticals has terminated its agreements with Orion Corporation, including...

7M ago

MRNS

Marinus Pharmaceuticals Merges with Immedica Pharma AB

Marinus ( ($MRNS) ) has provided an announcement. Marinus Pharmaceuticals has entered into a merger agreement with Immedica...

7M ago

MRNS

Marinus Pharmaceuticals to be acquired by Immedica for 55c per share

Immedica Pharma and Marinus Pharmaceuticals (MRNS) announced that they have entered into an agreement and plan of merger...

7M ago

MRNS

Marinus Unveils Management Retention and Severance Plans

The latest update is out from Marinus ( ($MRNS) ). Marinus Pharmaceuticals has announced a Senior Management Retention...

8M ago

MRNS

Marinus Pharmaceuticals Faces Financial Turmoil Amidst Class Action Lawsuit

Marinus Pharmaceuticals Inc (MRNS) has disclosed a new risk, in the Litigation & Legal Liabilities category. Marinus Pharmaceuticals...

9M ago

MRNS

Marinus Pharmaceuticals Reports Q3 Growth in ZTALMY Revenue

Marinus Pharmaceuticals Inc ( ($MRNS) ) has released its Q3 earnings. Here is a breakdown of the information...

9M ago

MRNS

Marinus Pharmaceuticals reports Q3 EPS (42c), consensus (41c)

Reports Q3 revenue $8.5M, consensus $9.4M. “This is a pivotal time for Sangamo as we build upon our...

9M ago

MRNS

Is MRNS a Buy, Before Earnings?

Marinus Pharmaceuticals Inc (MRNS) is scheduled to report 3rd quarter earnings on 11/05/2024. Regarding Q3 estimates, Wall Street...

9M ago

MRNS

Marinus Pharmaceuticals price target lowered to $1 from $3 at RBC Capital

RBC Capital lowered the firm’s price target on Marinus Pharmaceuticals (MRNS) to $1 from $3 and keeps a...

10M ago

MRNS

Marinus Pharmaceuticals price target lowered to $4 from $13 at Cantor Fitzgerald

Cantor Fitzgerald analyst Charles Duncan lowered the firm’s price target on Marinus Pharmaceuticals (MRNS) to $4 from $13...

10M ago

MRNS

MRNS FAQ

What was Marinus Pharmaceuticals Inc’s price range in the past 12 months?

Marinus Pharmaceuticals Inc lowest stock price was $0.22 and its highest was $10.50 in the past 12 months.

What is Marinus Pharmaceuticals Inc’s market cap?

Marinus Pharmaceuticals Inc’s market cap is $30.37M.

When is Marinus Pharmaceuticals Inc’s upcoming earnings report date?

Marinus Pharmaceuticals Inc’s upcoming earnings report date is Mar 11, 2025 which is 150 days ago.

How were Marinus Pharmaceuticals Inc’s earnings last quarter?

Currently, no data Available

Is Marinus Pharmaceuticals Inc overvalued?

According to Wall Street analysts Marinus Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Marinus Pharmaceuticals Inc pay dividends?

Marinus Pharmaceuticals Inc does not currently pay dividends.

What is Marinus Pharmaceuticals Inc’s EPS estimate?

Marinus Pharmaceuticals Inc’s EPS estimate is -0.33.

How many shares outstanding does Marinus Pharmaceuticals Inc have?

Marinus Pharmaceuticals Inc has 53,869,000 shares outstanding.

What happened to Marinus Pharmaceuticals Inc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Marinus Pharmaceuticals Inc?

Among the largest hedge funds holding Marinus Pharmaceuticals Inc’s share is Woodline Partners LP. It holds Marinus Pharmaceuticals Inc’s shares valued at 2M.

Marinus Stock Smart Score

Neutral

Fundamentals

Return on Equity

210.50%

Trailing 12-Months

Asset Growth

-68.32%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals, Inc. (MRNS) is a pharmaceutical company focused on developing innovative therapies to treat rare seizure disorders. The company's primary product, Ganaxolone, is a novel drug that acts as a GABA receptor modulator, designed to provide treatment options for patients with unmet medical needs, including those suffering from CDKL5 deficiency disorder and other seizure-related conditions.

Marinus (MRNS) Earnings & Revenues

Currently, no data available

Please return soon. This page is being updated.

Historic Earnings Reports

MRNS Stock 12 Month Forecast

Average Price Target

$0.95

▲(72.73% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","8":"$8","11":"$11","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$0.95</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.30</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2,5,8,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"Jun<br/>2024","9":"Oct<br/>2024","12":"Jan<br/>2025","25":"Jan<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.54,0.6523076923076924,0.7646153846153847,0.8769230769230769,0.9892307692307692,1.1015384615384616,1.2138461538461538,1.3261538461538462,1.4384615384615385,1.5507692307692307,1.6630769230769231,1.7753846153846153,1.8876923076923076,{"y":2,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.54,0.5715384615384616,0.6030769230769231,0.6346153846153846,0.6661538461538461,0.6976923076923076,0.7292307692307692,0.7607692307692308,0.7923076923076923,0.8238461538461538,0.8553846153846153,0.8869230769230769,0.9184615384615384,{"y":0.95,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.54,0.5215384615384616,0.5030769230769231,0.4846153846153846,0.46615384615384614,0.4476923076923077,0.42923076923076925,0.4107692307692308,0.3923076923076923,0.37384615384615383,0.35538461538461535,0.3369230769230769,0.31846153846153846,{"y":0.3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.32,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.4,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.99,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.92,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.97,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.47,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.42,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.4,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.4,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.67,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.33,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.33,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.54,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >

Similar Stocks

ACAD

ACADIA Pharmaceuticals

―

CPRX

Catalyst Pharma

―

SRPT

Sarepta Therapeutics

―

PTCT